Xencor, Inc. (NASDAQ:XNCR) Receives $36.00 Consensus PT from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $36.00.

XNCR has been the subject of several recent analyst reports. BTIG Research cut their target price on Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, April 16th. Wedbush reduced their price objective on shares of Xencor from $36.00 to $34.00 and set an “outperform” rating on the stock in a report on Wednesday, February 28th. StockNews.com raised shares of Xencor from a “sell” rating to a “hold” rating in a research note on Saturday, March 9th. Mizuho reduced their price target on shares of Xencor from $59.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, January 22nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $32.00 price objective on shares of Xencor in a research report on Wednesday, February 28th.

Xencor Stock Up 0.8 %

Shares of XNCR opened at $24.31 on Friday. The stock has a fifty day simple moving average of $21.85 and a two-hundred day simple moving average of $20.54. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.50 billion, a PE ratio of -11.58 and a beta of 0.77. Xencor has a 52-week low of $16.49 and a 52-week high of $28.96.

Xencor (NASDAQ:XNCR) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67). The firm had revenue of $44.70 million for the quarter, compared to analysts’ expectations of $77.63 million. Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. Xencor’s revenue for the quarter was up 106.9% on a year-over-year basis. During the same period last year, the firm earned ($0.20) earnings per share. As a group, equities analysts forecast that Xencor will post -3.25 EPS for the current year.

Insider Transactions at Xencor

In related news, VP John R. Desjarlais sold 54,108 shares of Xencor stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the completion of the transaction, the vice president now directly owns 161,675 shares in the company, valued at $3,133,261.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Xencor news, Director Kurt A. Gustafson sold 14,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $23.18, for a total transaction of $324,520.00. Following the completion of the transaction, the director now owns 6,007 shares in the company, valued at approximately $139,242.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP John R. Desjarlais sold 54,108 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total transaction of $1,048,613.04. Following the completion of the sale, the vice president now owns 161,675 shares in the company, valued at $3,133,261.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 101,351 shares of company stock valued at $2,152,417. 5.23% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xencor

Institutional investors and hedge funds have recently modified their holdings of the company. Primecap Management Co. CA lifted its position in shares of Xencor by 8.8% during the 4th quarter. Primecap Management Co. CA now owns 8,901,607 shares of the biopharmaceutical company’s stock worth $188,981,000 after buying an additional 717,401 shares during the last quarter. Vanguard Group Inc. grew its stake in Xencor by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 6,767,249 shares of the biopharmaceutical company’s stock worth $143,669,000 after buying an additional 115,886 shares during the last quarter. Armistice Capital LLC increased its position in Xencor by 1.5% during the fourth quarter. Armistice Capital LLC now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $31,845,000 after buying an additional 22,000 shares during the period. Invesco Ltd. lifted its stake in Xencor by 4.6% in the third quarter. Invesco Ltd. now owns 555,809 shares of the biopharmaceutical company’s stock valued at $11,200,000 after buying an additional 24,303 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Xencor by 6.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 520,698 shares of the biopharmaceutical company’s stock valued at $11,054,000 after acquiring an additional 32,251 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.